MINI REVIEW article
Front. Microbiol.
Sec. Systems Microbiology
Volume 16 - 2025 | doi: 10.3389/fmicb.2025.1632435
This article is part of the Research TopicMicrobial Therapeutics: Harnessing the Human Microbiome for Disease Treatment and PreventionView all 5 articles
The Human Microbiome in Clinical Translation: From Bench to Bedside
Provisionally accepted- 1Cancer Research Group (CRG), Faculty of Medicine, Universidad de Las Américas, Quito, Ecuador
- 2Grossman School of Medicine, New York University, New York, New York, United States
- 3Hospital Metropolitano de Quito, Quito, Ecuador
Select one of your emails
You have multiple emails registered with Frontiers:
Notify me on publication
Please enter your email address:
If you already have an account, please login
You don't have a Frontiers account ? You can register here
The human microbiome, once regarded as a passive passenger, is now recognized as a dynamic and essential determinant of human physiology, shaping immunity, metabolism, neurodevelopment, and therapeutic responsiveness across the lifespan. Advances in multi-omic technologies, experimental models, and computational approaches have revealed mechanistic insights into how microbial communities modulate host systems across diverse body sites, including the gut, skin, lungs, oral cavity, and reproductive tract. The clinical translation of this knowledge has begun to redefine early-life programming, cardiometabolic regulation, immune homeostasis, neuropsychiatric resilience, and cancer therapy response. Innovative strategies such as phage therapy, live biotherapeutics, precision nutrition, and microbiota transplantation illustrate the therapeutic potential of harnessing microbial functions to prevent or treat disease. In parallel, large-scale initiatives cataloging the microbiome of underexplored niches, such as the vagina and skin, are advancing health equity by broadening representation in microbial reference datasets. Yet significant challenges persist, including interindividual variability, incomplete functional annotation of microbial "dark matter," and the absence of validated biomarkers. Addressing these gaps requires standardized methodologies, harmonized regulatory frameworks, and longitudinal studies across diverse populations. This review outlines the progress and remaining hurdles in translating microbiome science into clinical practice and concludes that the microbiome now stands at the forefront of a paradigm shift, transforming concepts of disease etiology, therapeutic design, and the future of individualized medicine.
Keywords: Human microbiome, clinical translation, precision medicine, biomarkers, microbiota transplantation
Received: 16 Jun 2025; Accepted: 03 Sep 2025.
Copyright: © 2025 Bautista, Echeverría, Maldonado-Noboa, Ojeda- Mosquera, Hidalgo-Tinoco and López-Cortés. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
* Correspondence: Andrés López-Cortés, Cancer Research Group (CRG), Faculty of Medicine, Universidad de Las Américas, Quito, Ecuador
Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.